SI2268642T1 - 1'-substituirani karba-nukleozidni analogi za antivirusno zdravljenje - Google Patents

1'-substituirani karba-nukleozidni analogi za antivirusno zdravljenje

Info

Publication number
SI2268642T1
SI2268642T1 SI200931153T SI200931153T SI2268642T1 SI 2268642 T1 SI2268642 T1 SI 2268642T1 SI 200931153 T SI200931153 T SI 200931153T SI 200931153 T SI200931153 T SI 200931153T SI 2268642 T1 SI2268642 T1 SI 2268642T1
Authority
SI
Slovenia
Prior art keywords
nucleoside analogs
antiviral treatment
substituted carba
carba
substituted
Prior art date
Application number
SI200931153T
Other languages
English (en)
Slovenian (sl)
Inventor
Thomas Butler
Aesop Cho
Choung U. Kim
Oliver L. Saunders
Lijun Zhang
Jay Parrish
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40887058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2268642(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of SI2268642T1 publication Critical patent/SI2268642T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
SI200931153T 2008-04-23 2009-04-22 1'-substituirani karba-nukleozidni analogi za antivirusno zdravljenje SI2268642T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4726308P 2008-04-23 2008-04-23
US13944908P 2008-12-19 2008-12-19
EP09734175.4A EP2268642B1 (en) 2008-04-23 2009-04-22 1' -substituted carba-nucleoside analogs for antiviral treatment
PCT/US2009/041447 WO2009132135A1 (en) 2008-04-23 2009-04-22 1' -substituted carba-nucleoside analogs for antiviral treatment

Publications (1)

Publication Number Publication Date
SI2268642T1 true SI2268642T1 (sl) 2015-05-29

Family

ID=40887058

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200931153T SI2268642T1 (sl) 2008-04-23 2009-04-22 1'-substituirani karba-nukleozidni analogi za antivirusno zdravljenje
SI200931823T SI2937350T1 (en) 2008-04-23 2009-04-22 1'-SUBSTITUTED CARBON-NUCLEOUS ANALOGS FOR ANTIVIRUSAL TREATMENT
SI200930503T SI2280973T1 (sl) 2008-04-23 2009-04-22 Karbanukleozidni analogi za antivirusno zdravljenje

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI200931823T SI2937350T1 (en) 2008-04-23 2009-04-22 1'-SUBSTITUTED CARBON-NUCLEOUS ANALOGS FOR ANTIVIRUSAL TREATMENT
SI200930503T SI2280973T1 (sl) 2008-04-23 2009-04-22 Karbanukleozidni analogi za antivirusno zdravljenje

Country Status (32)

Country Link
US (5) US8008264B2 (enExample)
EP (3) EP2280973B1 (enExample)
JP (4) JP5425186B2 (enExample)
KR (3) KR101681559B1 (enExample)
CN (3) CN102015714B (enExample)
AP (2) AP3076A (enExample)
AR (1) AR071395A1 (enExample)
AU (2) AU2009240630B2 (enExample)
BR (2) BRPI0911410A2 (enExample)
CA (2) CA2722177C (enExample)
CO (2) CO6321235A2 (enExample)
CY (4) CY1113647T1 (enExample)
DK (3) DK2280973T3 (enExample)
EA (2) EA019883B1 (enExample)
EC (2) ECSP10010609A (enExample)
ES (3) ES2398684T3 (enExample)
HR (3) HRP20130048T1 (enExample)
HU (3) HUE025528T2 (enExample)
IL (2) IL208515A (enExample)
LT (2) LT2937350T (enExample)
LU (1) LUC00193I2 (enExample)
ME (1) ME03089B (enExample)
MX (2) MX2010011659A (enExample)
NO (1) NO2937350T3 (enExample)
NZ (2) NZ588670A (enExample)
PL (3) PL2280973T3 (enExample)
PT (3) PT2937350T (enExample)
RS (2) RS57092B1 (enExample)
SI (3) SI2268642T1 (enExample)
TW (2) TW201334784A (enExample)
WO (2) WO2009132135A1 (enExample)
ZA (2) ZA201007713B (enExample)

Families Citing this family (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CZ301182B6 (cs) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
ES2624353T3 (es) 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
AR071395A1 (es) 2008-04-23 2010-06-16 Gilead Sciences Inc Analogos carba-nucleosidos 1'-sustituidos para tratamiento antiviral
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
NZ593110A (en) 2008-12-09 2013-06-28 Gilead Sciences Inc pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
SG172359A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
HRP20130862T1 (hr) 2009-09-21 2013-10-25 Gilead Sciences, Inc. Procesi i intermedijeri za pripravu analoga 1'-cijanokarbanukleozida
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
ES2730805T3 (es) 2009-09-21 2019-11-12 Gilead Sciences Inc Análogos de carba-nucleósido sustituido por 2'-fluoro para el tratamiento antiviral
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
EP2493889B1 (en) 2009-10-30 2017-09-06 Janssen Pharmaceutica, N.V. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
JP2013527145A (ja) * 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
NZ606141A (en) 2010-07-19 2015-03-27 Gilead Sciences Inc Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
UA111163C2 (uk) * 2010-07-22 2016-04-11 Гайлід Сайєнсіз, Інк. Способи й сполуки для лікування вірусних інфекцій paramyxoviridae
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
WO2012039791A1 (en) * 2010-09-20 2012-03-29 Gilead Sciences, Inc. 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2012040124A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
CA2822037A1 (en) * 2010-12-20 2012-06-28 Gilead Sciences, Inc. Methods for treating hcv
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US8877744B2 (en) * 2011-04-04 2014-11-04 Hoffmann-La Roche Inc. 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
AU2012242978A1 (en) * 2011-04-13 2013-10-24 Merck Sharp & Dohme Corp. 2'-Cyano Substituted Nucleoside Derivatives and methods of use thereof for the treatment of viral diseases
BR112013026345A2 (pt) * 2011-04-13 2019-04-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
WO2012142075A1 (en) * 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
MX344600B (es) 2011-06-27 2016-12-20 Janssen Pharmaceutica Nv Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina.
US9408863B2 (en) 2011-07-13 2016-08-09 Merck Sharp & Dohme Corp. 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
US9416154B2 (en) 2011-07-13 2016-08-16 Merck Sharp & Dohme Corp. 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
WO2013039920A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
CA2840242C (en) 2011-09-16 2019-03-26 Gilead Sciences, Inc. Methods for treating hcv
SG11201401082XA (en) * 2011-09-30 2014-04-28 Kineta Inc Anti-viral compounds
WO2013056046A1 (en) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
GB2515942A (en) * 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
AU2013217224B2 (en) 2012-02-10 2017-04-06 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
WO2013138236A1 (en) * 2012-03-13 2013-09-19 Gilead Sciences , Inc. 2'- substituted carba-nucleoside analogs for antiviral treatment
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
BR112014029115A8 (pt) 2012-05-22 2018-04-03 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, uso de um composto ou composição
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
HK1206250A1 (en) 2012-06-26 2016-01-08 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and ped 10 inhibitors for use in the treatment of neurological or metabolic disorders
CN104411314B (zh) 2012-07-09 2017-10-20 詹森药业有限公司 磷酸二酯酶10的抑制剂
WO2014035140A2 (en) * 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
WO2014042433A2 (en) * 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
WO2014052638A1 (en) * 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
CN104936970A (zh) 2012-10-08 2015-09-23 埃迪尼克斯医药公司 用于hcv感染的2′-氯核苷类似物
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
WO2014059902A1 (en) * 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
WO2014059901A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
RU2015123641A (ru) 2012-11-19 2017-01-10 Мерк Шарп И Доум Корп. 2-алкинилзамещенные производные нуклеозидов, предназначенные для лечения вирусных заболеваний
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
KR20200060782A (ko) 2013-01-31 2020-06-01 길리애드 파마셋 엘엘씨 두 항바이러스 화합물의 병용 제형물
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
WO2014204831A1 (en) 2013-06-18 2014-12-24 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
EP3074399A1 (en) * 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
EA201790024A1 (ru) 2014-07-11 2017-07-31 Джилид Сайэнс, Инк. Модуляторы toll-подобных рецепторов для лечения вич
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
WO2016023522A2 (en) 2014-08-15 2016-02-18 Merck Sharp & Dohme Corp. Substituted phosphoramidate compounds and uses thereof
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
WO2016033164A1 (en) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
US9738646B2 (en) 2014-09-16 2017-08-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
US20170334941A1 (en) * 2014-10-31 2017-11-23 Cocrystal Pharma, Inc. 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
WO2016073756A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN107428792B (zh) 2014-12-15 2023-01-24 埃默里大学 用于治疗乙型肝炎病毒的磷酰胺
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
EA039561B1 (ru) * 2015-01-20 2022-02-10 Джилид Сайэнс, Инк. Соединения для лечения вирусных инфекций filoviridae
MY190867A (en) 2015-03-06 2022-05-13 Atea Pharmaceuticals Inc ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
US10618926B2 (en) 2015-04-02 2020-04-14 Merck Sharp & Dohme Process for making phosphoramidate protected nucleoside compounds
US10011629B2 (en) 2015-05-01 2018-07-03 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
WO2016180743A1 (en) * 2015-05-12 2016-11-17 F. Hoffmann-La Roche Ag Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
US9855289B2 (en) 2015-08-05 2018-01-02 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
MA52371A (fr) 2015-09-16 2021-09-22 Gilead Sciences Inc Méthodes de traitement d'infections dues aux coronaviridae
WO2017053216A2 (en) 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
CN109071467B (zh) 2016-03-09 2023-04-04 艾丽奥斯生物制药有限公司 无环抗病毒药
WO2017172596A1 (en) 2016-03-28 2017-10-05 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
WO2017184668A1 (en) * 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
CA3029315A1 (en) 2016-06-24 2017-12-28 Emory University Phosphoramidates for the treatment of hepatitis b virus
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EP3497111A2 (en) * 2016-08-12 2019-06-19 Janssen BioPharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
PL3512863T3 (pl) 2016-09-07 2022-04-04 Atea Pharmaceuticals, Inc. 2'-Podstawione-N6-podstawione nukleotydy purynowe do leczenia zakażeń wirusem RNA
WO2018129039A1 (en) 2017-01-04 2018-07-12 President And Fellows Of Harvard College Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same
IL295609B2 (en) 2017-02-01 2023-11-01 Atea Pharmaceuticals Inc Nucleotide hemisulfate salt for the treatment of hepatitis C virus
CA3056072C (en) 2017-03-14 2022-08-23 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
JP2020518578A (ja) 2017-05-01 2020-06-25 ギリアード サイエンシーズ， インコーポレイテッド （Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態
ES3000461T3 (en) 2017-07-11 2025-02-28 Gilead Sciences Inc Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
TWI624264B (zh) * 2017-08-11 2018-05-21 景鑫生物科技股份有限公司 南洋山蘇水萃物的用途
KR102696517B1 (ko) 2017-09-18 2024-08-21 얀센 바이오파마, 인크. 치환된 뉴클레오시드, 뉴클레오티드 및 이들의 유사체
PL3706762T3 (pl) 2017-12-07 2025-02-10 Emory University N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
MX2020006864A (es) * 2017-12-27 2020-11-11 Univ Emory Modalidades combinadas para inhibidores de nucleosidos y/o nadph oxidasa (nox) como agentes antivirales especificos de mieloides.
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
WO2020197991A1 (en) 2019-03-22 2020-10-01 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
JP7621974B2 (ja) 2019-05-09 2025-01-27 アリゴス セラピューティクス インコーポレイテッド Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物
EP4008720A4 (en) * 2019-08-02 2023-08-02 BeiGene, Ltd. IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVE USED AS A TLR8 AGONIST
CN110724174B (zh) * 2019-09-10 2021-02-05 广州六顺生物科技股份有限公司 吡咯并三嗪类化合物、组合物及其应用
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
CN113214262B (zh) * 2020-02-05 2023-07-07 华创合成制药股份有限公司 一种含有胍基的化合物及其制备方法和用途
CN113214334A (zh) * 2020-02-05 2021-08-06 华创合成制药股份有限公司 用于治疗病毒感染的化合物及其制备方法和用途
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
AR121356A1 (es) 2020-02-18 2022-05-11 Gilead Sciences Inc Compuestos antivirales
TWI791193B (zh) 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
CN113292565B (zh) * 2020-02-24 2023-01-31 浙江森科建设有限公司 核苷类化合物及其制备方法和应用
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN111269248A (zh) * 2020-03-05 2020-06-12 江苏福瑞康泰药业有限公司 一种核苷氨基磷酸酯类药物母液回收的新方法
TWI890963B (zh) 2020-03-12 2025-07-21 美商基利科學股份有限公司 1'-氰基核苷之製備方法
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
CN115315252A (zh) * 2020-03-22 2022-11-08 盈擘医药股份有限公司 用于预防或暴露后治疗感染或呼吸疾病的抗病毒组合物
WO2021202669A2 (en) 2020-04-01 2021-10-07 Reyoung Corporation Nucleoside and nucleotide conjugate compounds and uses thereof
AU2021251689B2 (en) 2020-04-06 2024-06-13 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CN112778310B (zh) * 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN115605492B (zh) * 2020-04-21 2025-09-16 配体制药股份有限公司 核苷酸前药化合物
TW202532084A (zh) 2020-05-29 2025-08-16 美商基利科學股份有限公司 瑞德西韋之治療方法
IL299202A (en) 2020-06-24 2023-02-01 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
TW202207916A (zh) * 2020-07-23 2022-03-01 薩摩亞商吉亞生技控股股份有限公司 治療病毒感染之方法及組合物
CA3185450A1 (en) 2020-08-06 2022-02-10 Istvan Borza Remdesivir intermediates
CN111956630A (zh) * 2020-08-20 2020-11-20 大连理工大学 一种瑞德西韦供雾化器用的液体制剂、制备方法及其应用
US11773122B2 (en) 2020-08-24 2023-10-03 Gilead Sciences. Inc. Phospholipid compounds and uses thereof
PE20231983A1 (es) 2020-08-27 2023-12-12 Gilead Sciences Inc Compuestos y metodos para el tratamiento de infecciones virales
CN114149434A (zh) * 2020-09-08 2022-03-08 安徽诺全药业有限公司 一种杂环化合物及其制备方法、应用
TWI811812B (zh) * 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
WO2022098371A1 (en) * 2020-11-09 2022-05-12 Yan Matthew Prodrugs of 1'-substituted carba-nucleoside analogues for antiviral treatment
PT4244396T (pt) 2020-11-11 2025-10-20 Gilead Sciences Inc Métodos de identificação de doentes com hiv sensíveis à terapia com anticorpos dirigidos ao sítio de ligação cd4 da gp120
CN112494500B (zh) * 2020-11-26 2022-01-11 北京箭牧科技有限公司 瑞德西韦在制备治疗抗肿瘤药物心脏毒性药物中的应用
CN114621229B (zh) * 2020-12-11 2024-07-02 嘉兴金派特生物科技有限公司 治疗或预防猫传染性腹膜炎的化合物或组合物
CN112592348B (zh) * 2020-12-21 2022-03-08 南京法恩化学有限公司 一种4-氨基吡咯并[2,1-f][1,2,4]三嗪的制备方法
EP4267582A4 (en) * 2020-12-30 2024-06-05 Southern University of Science and Technology METHODS AND MODIFIED NUCLEOSIDES FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
ES3028915T3 (en) 2021-04-16 2025-06-20 Gilead Sciences Inc Methods of preparing carbanucleosides using amides
BR112023026356A2 (pt) 2021-06-17 2024-03-05 Atea Pharmaceuticals Inc Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c
KR20230001208A (ko) 2021-06-28 2023-01-04 동아대학교 산학협력단 오각고리 염기를 포함하는 비고리형 핵산 모방체
CN115703796A (zh) * 2021-08-09 2023-02-17 苏州恩泰新材料科技有限公司 一种瑞德西韦重要中间体制备方法
EP4387977A1 (en) 2021-08-18 2024-06-26 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
PL4445900T3 (pl) 2021-12-03 2025-09-22 Gilead Sciences, Inc. Związki terapeutyczne przeciwko zakażeniu wirusem hiv
WO2023102529A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CA3244278A1 (en) 2022-03-02 2023-09-07 Gilead Sciences Inc COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
CN114437159B (zh) * 2022-04-11 2022-06-28 佛山市晨康生物科技有限公司 一种环状碳酸酯核苷类化合物及其应用
AU2023261450A1 (en) * 2022-04-25 2024-11-14 Miracure Biotechnology Limited Nucleoside drug for treating or preventing coronavirus infection, and use thereof
EP4547665A1 (en) * 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
TW202434566A (zh) 2022-07-01 2024-09-01 美商基利科學股份有限公司 可用於hiv病毒感染之疾病預防性或治療性治療的治療性化合物
CA3265134A1 (en) 2022-08-26 2024-02-29 Gilead Sciences Inc DOSING AND PLANNING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES
EP4598934A1 (en) 2022-10-04 2025-08-13 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
EP4605396A1 (en) * 2022-10-23 2025-08-27 Shanghai Curegene Pharmaceutical Co., Ltd. Anticoronviral compounds and compositions and uses thereof
WO2024088184A1 (en) * 2022-10-23 2024-05-02 Shanghai Curegene Pharmaceutical Co., Ltd. Anti-feline-coronavirus compounds and uses thereof
CN115819423B (zh) * 2022-11-29 2024-11-22 武汉大学 一种瑞德西韦或其中间体的protac化合物及其制备方法与抗ev71的应用
AU2024259111A1 (en) 2023-04-19 2025-10-16 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
CN118852168B (zh) * 2023-04-26 2025-09-19 深圳科兴药业有限公司 一种制备苄基碳核苷类似物的新方法及其应用
CN116217621B (zh) * 2023-04-26 2023-08-11 北京沐华生物科技有限责任公司 一种核苷类双前药、合成方法及应用
US20250011352A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Solid forms
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於ｈｉｖ之治療性化合物
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
US20250127801A1 (en) 2023-10-11 2025-04-24 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250122219A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250120989A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
WO2025184609A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Antiviral compounds
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250296932A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
JPS59141856A (ja) 1983-02-02 1984-08-14 Fuji Electric Co Ltd Ｆｓ変復調方式
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DE69115694T2 (de) 1990-06-13 1996-10-17 Arnold Newton Mass. Glazier Phosphorylierte prodrugs
DE10399025I2 (de) 1990-09-14 2007-11-08 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
US6887707B2 (en) 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
JP2002527519A (ja) 1998-10-16 2002-08-27 メルク シャープ エンド ドーム リミテッド Ｇａｂａ受容体のリガンドとしてのピラゾロトリアジン誘導体
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
WO2001019375A1 (en) 1999-09-15 2001-03-22 Biocryst Pharmaceuticals, Inc. Inhibiting t-cell proliferation
AU1262001A (en) 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
HUP0301112A3 (en) 2000-02-18 2005-04-28 Shire Biochem Inc Laval Method for the treatment or prevention of flavivirus infections using nucleoside analogues
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CZ301182B6 (cs) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
KR101005299B1 (ko) 2000-10-18 2011-01-04 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
HUP0400726A3 (en) 2001-01-22 2007-05-29 Merck & Co Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US20040006002A1 (en) * 2001-09-28 2004-01-08 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
AT410792B (de) 2001-12-28 2003-07-25 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung
AU2003217863B9 (en) 2002-02-28 2009-10-29 Biota Scientific Management Pty Ltd Nucleotide mimics and their prodrugs
CA2477795A1 (en) 2002-02-28 2003-09-12 Kandasamy Sakthivel Nucleoside 5'-monophosphate mimics and their prodrugs
US20040138170A1 (en) 2002-03-06 2004-07-15 Montgomery John A. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
GB0210127D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
AU2003232071A1 (en) 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
AU2003233667A1 (en) 2002-05-23 2003-12-12 Biocryst Pharmaceuticals, Inc. Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
ES2624353T3 (es) 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
AU2004233898B2 (en) 2003-04-25 2010-12-23 Gilead Sciences, Inc. Antiviral phosphonate analogs
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
ATE478886T1 (de) 2003-07-25 2010-09-15 Idenix Pharmaceuticals Inc Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
CA2537114C (en) 2003-08-27 2012-10-02 Biota, Inc. Tricyclic nucleosides or nucleotides as therapeutic agents
JP5055564B2 (ja) * 2004-06-15 2012-10-24 メルク・シャープ・エンド・ドーム・コーポレイション Ｒｎａ依存性ｒｎａウイルスポリメラーゼの阻害剤としてのｃ−プリンヌクレオシド類似体
US7560434B2 (en) 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
WO2006065335A2 (en) 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
CN101043893A (zh) 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
KR20070100237A (ko) 2004-10-29 2007-10-10 바이오크리스트 파마수티컬즈, 인코퍼레이티드 치료용 푸로피리미딘 및 티에노피리미딘
AU2006222563A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
EP1863500A2 (en) 2005-03-29 2007-12-12 Biocryst Pharmaceuticals, Inc. Hepatitis c therapies
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
AP2870A (en) 2005-10-03 2014-03-31 Univ Health Network Odcase inhibitors for the treatment of malaria
WO2007056170A2 (en) 2005-11-02 2007-05-18 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
MX2008007103A (es) 2005-12-02 2008-09-12 Bayer Healthcare Llc Derivados 4-amino-pirrolotriazina sustituidos, útiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis.
WO2007097991A2 (en) 2006-02-16 2007-08-30 Pharmasset, Inc. Methods and kits for dosing of antiviral agents
CL2007001427A1 (es) 2006-05-22 2008-05-16 Novartis Ag Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
WO2008005542A2 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
WO2008033466A2 (en) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
ITBO20060683A1 (it) 2006-10-03 2008-04-04 Sympak Corazza S P A Dispositivo per il raggruppamento di confezioni.
CA2672613A1 (en) 2006-12-20 2008-07-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
SG177974A1 (en) 2007-01-12 2012-02-28 Biocryst Pharm Inc Antiviral nucleoside analogs
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CA2685520A1 (en) * 2007-05-10 2008-11-20 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
AR071395A1 (es) 2008-04-23 2010-06-16 Gilead Sciences Inc Analogos carba-nucleosidos 1'-sustituidos para tratamiento antiviral
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
WO2010036407A2 (en) * 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
NZ594370A (en) 2009-02-10 2014-01-31 Gilead Sciences Inc Carba-nucleoside analogs for antiviral treatment
ES2519568T3 (es) 2009-03-24 2014-11-07 Biocryst Pharmaceuticals, Inc. Sales farmacéuticas útiles de 7-[(3R,4R)-3-hidroxi-4-hidroximetil-pirrolidin-1-ilmetil]-3,5-dihidro-pirrolo[3,2-d]pirimidin-4-ona
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
ES2730805T3 (es) 2009-09-21 2019-11-12 Gilead Sciences Inc Análogos de carba-nucleósido sustituido por 2'-fluoro para el tratamiento antiviral
HRP20130862T1 (hr) 2009-09-21 2013-10-25 Gilead Sciences, Inc. Procesi i intermedijeri za pripravu analoga 1'-cijanokarbanukleozida
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
NZ606141A (en) 2010-07-19 2015-03-27 Gilead Sciences Inc Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
UA111163C2 (uk) 2010-07-22 2016-04-11 Гайлід Сайєнсіз, Інк. Способи й сполуки для лікування вірусних інфекцій paramyxoviridae
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
WO2012039791A1 (en) 2010-09-20 2012-03-29 Gilead Sciences, Inc. 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
EP2627334B1 (en) 2010-10-15 2015-04-29 Biocryst Pharmaceuticals, Inc. Compositions for use in the treatment of viral infections

Also Published As

Publication number Publication date
EP2280973B1 (en) 2012-11-28
HRP20180572T1 (hr) 2018-05-18
CN102046626A (zh) 2011-05-04
JP2011521903A (ja) 2011-07-28
HRP20130048T1 (hr) 2013-02-28
KR101681559B1 (ko) 2016-12-01
JP5425186B2 (ja) 2014-02-26
CY1120366T1 (el) 2019-07-10
NZ588670A (en) 2012-08-31
ECSP10010609A (es) 2010-12-30
DK2280973T3 (da) 2013-03-04
EP2937350B1 (en) 2018-01-10
JP2011518835A (ja) 2011-06-30
BRPI0911410A2 (pt) 2015-10-06
BRPI0910455A2 (pt) 2018-02-14
ZA201008008B (en) 2011-07-27
CN102015714A (zh) 2011-04-13
EA020659B1 (ru) 2014-12-30
ZA201007713B (en) 2011-07-27
CA2722084C (en) 2016-08-23
LTPA2020539I1 (lt) 2021-01-11
USRE46762E1 (en) 2018-03-27
HK1154010A1 (en) 2012-04-20
PT2280973E (pt) 2013-02-04
CA2722177C (en) 2016-08-16
PT2937350T (pt) 2018-04-16
CA2722084A1 (en) 2009-10-29
AP2010005414A0 (en) 2010-10-31
HK1216750A1 (en) 2016-12-02
HUE025528T2 (en) 2016-05-30
AR071395A1 (es) 2010-06-16
AU2009240642B2 (en) 2013-08-29
US20100021425A1 (en) 2010-01-28
RS57092B1 (sr) 2018-06-29
TWI401084B (zh) 2013-07-11
NZ588400A (en) 2012-08-31
CY2020044I1 (el) 2021-03-12
KR20160138591A (ko) 2016-12-05
LTC2937350I2 (lt) 2022-05-10
KR101856404B1 (ko) 2018-05-09
MX2010011661A (es) 2010-11-30
AP2010005439A0 (en) 2010-10-31
CY2020044I2 (el) 2021-03-12
DK2937350T3 (en) 2018-04-23
HRP20150359T1 (hr) 2015-05-22
EA201071128A1 (ru) 2011-08-30
KR20110004883A (ko) 2011-01-14
AU2009240630B2 (en) 2013-07-18
PL2268642T3 (pl) 2015-08-31
HK1152709A1 (en) 2012-03-09
JP2014012739A (ja) 2014-01-23
ME03089B (me) 2019-01-20
US8318682B2 (en) 2012-11-27
IL208701A0 (en) 2010-12-30
US20110293563A1 (en) 2011-12-01
LUC00193I2 (enExample) 2024-07-01
ES2536193T3 (es) 2015-05-21
DK2268642T3 (en) 2015-05-26
IL208515A (en) 2016-04-21
EP2280973A1 (en) 2011-02-09
AP3237A (en) 2015-04-30
TW201002331A (en) 2010-01-16
AU2009240642A1 (en) 2009-10-29
US20130344028A2 (en) 2013-12-26
CY1113647T1 (el) 2016-06-22
BRPI0910455B8 (pt) 2021-05-25
RS54008B1 (sr) 2015-10-30
ES2665272T3 (es) 2018-04-25
CO6321235A2 (es) 2011-09-20
AU2009240630A1 (en) 2009-10-29
IL208701A (en) 2016-03-31
PL2280973T3 (pl) 2013-05-31
CN102015714B (zh) 2014-09-24
CO6300958A2 (es) 2011-07-21
EA019883B1 (ru) 2014-07-30
EP2268642B1 (en) 2015-02-25
SI2280973T1 (sl) 2013-03-29
EP2937350B9 (en) 2022-08-17
JP5425187B2 (ja) 2014-02-26
WO2009132123A1 (en) 2009-10-29
PL2937350T3 (pl) 2018-06-29
EA201071170A1 (ru) 2011-08-30
ECSP10010618A (es) 2011-03-31
EP2268642A1 (en) 2011-01-05
HUE038946T2 (hu) 2018-12-28
US20130034521A1 (en) 2013-02-07
HUS2000055I1 (hu) 2021-01-28
BRPI0910455B1 (pt) 2020-10-27
US8008264B2 (en) 2011-08-30
US8853171B2 (en) 2014-10-07
KR20110005888A (ko) 2011-01-19
WO2009132135A1 (en) 2009-10-29
US20090317361A1 (en) 2009-12-24
TW201334784A (zh) 2013-09-01
IL208515A0 (en) 2010-12-30
ES2398684T3 (es) 2013-03-21
EP2937350A1 (en) 2015-10-28
CN104262345B (zh) 2017-06-23
NO2937350T3 (enExample) 2018-06-09
CA2722177A1 (en) 2009-10-29
LT2937350T (lt) 2018-04-10
SI2937350T1 (en) 2018-05-31
US8012941B2 (en) 2011-09-06
MX2010011659A (es) 2010-11-30
CN104262345A (zh) 2015-01-07
KR101645742B1 (ko) 2016-08-04
CY1116425T1 (el) 2017-02-08
AP3076A (en) 2014-12-31
PT2268642E (pt) 2015-06-02
JP2014040471A (ja) 2014-03-06

Similar Documents

Publication Publication Date Title
HUS2000055I1 (hu) 1'-szubsztituált carba-nukleozid analógok antivirális kezelésre
IL248110A0 (en) Analogues of carba-nucleoside that are converted at the 2-position in fluorine for antiviral treatment
AP2922A (en) Carbra-nucleoside analogs for antiviral treatment
AP3699A (en) 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
ZA201104638B (en) Nucleoside analogs
PL2576534T3 (pl) 1'-podstawione proleki karbanukleozydów do leczenia przeciwwirusowego
IL199664A0 (en) Antiviral nucleoside analogs
TH0901001785B (th) สารคล้ายคาร์บา-นิวคลิโอไซด์ที่ถูกแทนที่ที่ตำแหน่ง 1' สำหรับการบำบัดต้านไวรัส